Recent advances in the treatment of infections due to resistant Staphylococcus aureus

Current Opinion in Infectious Diseases

Volumn 17, Issue 6, 2004, Pages 549-555

  Anstead, Gregory M ^a,b   Owens, Aaron D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Dalbavancin; Daptomycin; Linezolid; Oritavancin; Tigecycline

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEFAZOLIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MINOCYCLINE; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RESISTANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; REVIEW; RHABDOMYOLYSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; THROMBOPHLEBITIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; HUMANS; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VIRGINIAMYCIN;

EID: 10344245591     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200412000-00007     Document Type: Review

References (47)

1. Lindsay JA, Holden MTG. Staphylococcus aureus: superbug, super genome? Trends Microbiol 2004; 12:378-385. An outstanding review of the genetics of S. aureus written at a level that is mostly comprehensible to those of us who are not molecular biologists.
2. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-2984. This well-done study compares the epidemiologic and microbiologic characteristics of community-associated MRSA cases with nosocomial cases.
3. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39:539-545. An excellent succinct review of the epidemiology, resistance mechanisms, identification, containment and treatment of S. aureus isolates with reduced susceptibility to vancomycin.
4. Anonymous. Vancomycin-resistance Staphylococcus aureus-New York, 2004. MMWR Morb Mort Wkly Rep 2004; 53:322-323.
5. Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant Stapylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2004; 52:864-868. A comprehensive examination of the antibiotic susceptibility pattern of the second VRSA isolate in the USA.
6. Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis 2003; 22:S178-S185.
7. von Eiff C, Lubritz G, Heese C, et al. Effect of trimethoprim- sulfamethoxazole in AIDS patients on the formation of the small colony variant phenotype of Staphyloccoccus aureus. Diagn Microbiol Infect Dis 2004; 48:191-194.
8. Reynolds R, Potz N, Colman M, et al. Antimicrobial susceptibility of the pathogens of bactearemia in UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53:1018-1032. A very comprehensive assessment of the in vitro activity of 16 antibiotics against 16 common Gram-positive and Gram-negative organisms.
9. Pavoni GL, Gianella M, Falcone M, et al. Conservative medical therapy of prosthetic joint infections; retrospective analysis of an 8-year experience. Clin Microbiol Infect 2004; 10:831-837.
10. Krut O, Sommer H, Kranke M. Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells. J Antimicrob Chemother 2004; 53:167-173. An interesting paper that examines the effects of antibiotics on bacterial growth in non-phagocytic cells, an issue that has not been addressed previously.
11. Shopsin B, Zhao X, Kreiswirth BN, et al. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004; 24:32-34.
12. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51 (Suppl S2):ii9-ii16. An excellent overview of linezolid's mechanism of action and discussion of its antibacterial spectrum.
13. Wunderink RG, Bello J, Cammarata SK, et al. Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methacillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797. This study demonstrates the superiority of linezolid in the treatment of Gram-positive and MRSA nosocomial pneumonia.
14. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intens Care Med 2004; 30:388-394. This is a seminal study that demonstrates the superiority of linezolid in the treatment of ventilator-associated Gram-positive and MRSA pneumonia.
15. Ioanas M, Lode H. Linezolid in VAP by MRSA: better choice? Intens Care Med 2004; 30:343-346.
16. 90 values (≤4 mg/l) for S. aureus.
17. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 2004; 32:8-14.
18. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47:3964-3966. A well-done study that examines penetration of linezolid into infected bone and periarticular tissue.
19. Lipsky BA, Itani K, Norden C, Linezolid Diabetic Foot Infection Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampillin-sulbactam/amoxicillin- clavulanate. Clin Infect Dis 2004; 38:17-24. This is the largest published trial of the outcome of treating diabetic foot infections (n = 371). For patients with foot ulcers, 81% were cured in the linezolid arm, compared with 68% in the aminopenicillin-β-lactamase inhibitor arm (P = 0.018). For patients without osteomyelitis, 87% were cured in the linezolid group, compared with 72% in the comparator (P = 0.003). Linezolid was associated with more-adverse effects, but there were similar rates of discontinuation of study drugs in both arms of the trial. In the subset of linezolid-treated patients infected with both Gram-positive and Gram-negative bacteria, clinical success rates were similar regardless of whether aztreonam was added, indicating that treating the Gram-positive organisms is more important to the outcome.
20. Nasaraway SA, Short AF, Kuter DJ, et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37:1609-1616. Nasaraway et al. assessed the risk of thrombocytopenia in 686 patients with nosocomial pneumonia who received linezolid or vancomycin for ≥5 days. New-onset thrombocytopenia occurred in 6.4% of the linezolid patients compared with 7.7% of those receiving vancomycin.
21. Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic devices. Clin Infect Dis 2004; 38:1058-1064. In a prospective, nonrandomized, observational study of patients with orthopedic infections who received long-term treatment with either vancomycin (n = 52) or linezolid (n = 20), there was no significant difference in the platelet counts between the treatment groups. One curious finding is that the subset of patients that received vancomycin prior to linezolid had a higher incidence of thrombocytopenia. Thrombocytopenia on linezolid therapy occurred gradually, at a mean of 40 days after starting the drug and was reversible 7-10 days after linezolid was stopped.
22. Anonymous. Pfizer: Zyvox (linezolid). Safety-nervous-psychiatric. Reports of peripheral or optic neuropathy. Data on file, 2004.
23. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159-168.
24. Legout L, Senneville E, Gomel JJ, et al. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38:767-768.
25. Frippiat F, Bergiers C, Michel C, et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Agents Chemother 2004; 53:114-115.
26. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32:137-143. A pharmacoeconomic analysis of linezolid compared to other intensive care unit interventions.
27. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect 2003; 4:45-58. This paper demonstrates the intrinsic cost advantage of using an effective oral antibiotic (linezolid) compared to a parenteral antibiotic (vancomycin).
28. Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Therapeut 2003; 10:264-274.
29. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrence and resistance profiles among infected patients in the intensive care unit report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004; 24:11-18. An excellent overall of antibiotic susceptibilities of common nosocomial pathogens (a total of 1321 strains) obtained from 25 intensive care units in the USA and Canada. In this study, 51.4% of S. aureus isolates were methicillin-resistant.
30. Lomaestro BM. Resistance to linezolid. Are we surprised? How hard should we look? Ann Pharmacother 2003; 37:909-911. A succinct review of bacterial resistance to linezolid and susceptibility testing.
31. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004; 64:445-455. A comprehensive review of the pharmacology of daptomycin.
32. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
33. Alder JD, Thorne G, Luperchio S, et al. Daptomycin compared to semi-synthetic penicillins or vancomycin for treatment of complicated skin and skin structure infections (cSSSI) caused by S. aureus. In: Program and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America. Alexandria, VA: Infectious Diseases Society of America; 2003. Abstract 296.
34. Cubist Pharmaceuticals. Data on file.
35. Klastersky J. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treatment Rep 2003; 29:431-440.
36. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26:511-532. A comprehensive review of the mechanisms of action of the glycopeptide antibiotics.
37. Mercier R-C, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enteracoccus faecium. Antimicrob Agents Chemother 1997; 41:1307-1312.
38. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 2000; 44:2991-2998.
39. Giamarellou H, O'Riordan W, Harris H, et al. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI). In: Program and Abstracts of the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 14-17 September 2003; Chicago, IL; Washington, DC: American Society for Microbiology; 2003. L-739a.
40. Wasilewski M, Disch D, McGill J, et al. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin-skin structure infections (cSSSI). In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2001 Chicago, IL; Washington, DC: American Society for Microbiology; 2001. Abstract UL-18.
41. van Bambeke F, van Laethem Y, Courvalin P, Tulkens P. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004; 64:913-936. A comprehensive review of the pharmacology of glycopeptide antibiotics.
42. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940-945.
43. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-1303.
44. Vicuron Pharmaceuticals. Press release. Vicuron Pharmaceuticals announces positive pivotal phase III results for dalbavancin in skin and soft tissue infections. Vicuron Pharmaceuticals 12 August 2004. http://biz.yahoo.com/ prnews/040812/sfth039_1.html [Accessed 16 June 04].
45. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines. A comparative review with the tetracyclines. Drugs 2004; 64:63-88. A comprehensive review of the pharmacology of the glycylcyclines.
46. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Therapeut 2004; 26:704-714. This is the first clinical trial of tigecycline in infections due Gram-positive pathogens.
47. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38:864-870. A superb overview of this controversial issue.